Multiply Labs' goal is to enable scalable, high-throughput manufacturing while maintaining rigorous quality and regulatory standards.

AstraZeneca is showing no signs of restarting a 200 million pound sterling ($273 million) investment in its U.K. hometown, despite keeping its options open. | AstraZeneca is showing no signs of ...

AstraZeneca had already bagged the rights to the AbelZeta Pharma-partnered CAR-T cell therapy for most of the world. | The ...

AstraZeneca is relying on several upcoming products to help hit its target of $80 billion in revenue by 2030, including drugs ...

By Andrew MacAskill LONDON, Jan 26 (Reuters) - UK-headquartered pharmaceutical firm AstraZeneca's CEO Pascal Soriot will join Prime Minister Keir Starmer's trip to China this week, said a source ...

SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as ...

AstraZeneca’s $80 billion revenue target for 2030 is “very much within reach,” Chief Fin | While the $80 billion revenue ...

A longtime former AstraZeneca Pharmaceuticals LP employee is suing the company, alleging she was discriminated against as a ...

Shares of AstraZeneca (NASDAQ: AZN) have jumped more than 10% this week. On Monday, the British drugmaker reported positive results from a clinical study of Enhertu in treating HER2-positive early ...

On Thursday, Conduit Pharmaceuticals Inc. (NASDAQ:CDT) entered into an agreement with AstraZeneca Plc (NASDAQ:AZN) to exclusively license rights to develop AZD1656 and AZD5658, both HK-4 glucokinase ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Short Sellers. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against ...

Anglo-Swedish pharma major AstraZeneca has provided notice of its withdrawal from listing of its American Depositary Shares ...